New Paradigms in M0 CRPC.

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

New Horizons for SMA.

Novel Regimens and Considerations in Radionuclide Therapy for mCRPC

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Updates and Insights on the Medical Science of Prostate Cancer

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Relapsed/Refractory Follicular Lymphoma Conundrums

Clinical Developments in Inflammatory Arthritis 2017

Updates on Emerging GLP-1 Receptor Agonists

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

Applying New Data in Practice:

Progression After Cancer Immunotherapy in Advanced NSCLC

The HCV Revolution: Are You and Your Practice Ready?

Prolonging Progression-Free Survival in Follicular Lymphoma

Mid-Year Hemophilia Update

Moving Evidence into Practice: Breast Cancer Highlights From Chicago

PARP Inhibitors and Cancer: What Do You Need to Know?

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Evolving Role of Immunotherapy in NSCLC

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Updates in Detection and Management of BCRPC

Management Challenges in CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

PCSK9 Inhibitors and Cardiovascular Outcomes

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Targeting BTK Signaling in B-Cell Malignancies

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Braf-MUTATION POSITIVE melanoma: a case conference

Novel Approaches in T1D Management

New Data on Emerging Treatments for Psoriasis

How to Select Therapy In Newly Diagnosed CLL

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

Evolving Concepts in the Management of Head and Neck Cancers

Future Directions in Myelofibrosis: Implications of Emerging Approaches.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Updates in the Management of Acute Promyelocytic Leukemia

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

FDA Approvals for Systemic Treatment of Prostate Cancer in 2018

PARP Inhibitors.

Locally Advanced Lung Cancer

Tackling Schizophrenia With Your Patients

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

Evaluating BTK Inhibitors in CLL

FLT3 Inhibitors in AML.

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

The ABCs of Pharmacogenomics in Clinical Practice

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Prioritizing Prevention of HPV-Related Disease

Peanut Allergy Immunotherapy

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

New Paradigms in M0 CRPC

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Case Study Presentation

Case Study Presentation (cont)

Managing M0 CRPC

Changes to Guidelines for Managing M0 CRPC

PROSPER Trial Enzalutamide in M0 CRPC

PROSPER MFS Favoring Enzalutamide

PROSPER PSA Progression

PROSPER First Use of Subsequent Antineoplastic Therapy

PROSPER Adverse Events

PROSPER Patient-Reported Outcomes

SPARTAN Trial Apalutamide in M0 CRPC

SPARTAN MFS

SPARTAN Prespecified Secondary and Exploratory Efficacy Endpoints

SPARTAN Updated Analysis of PFS2 with First Subsequent Therapy and Safety

SPARTAN AEs With Apalutamide vs Placebo

SPARTAN Quality of Life Mean Scores

Next-Generation Androgen Receptor Inhibitors

ARAMIS Trial Darolutamide in M0 CRPC

ARAMIS MFS

ARAMIS OS

ARAMIS Time to Pain Progression (BPI-SF)

ARAMIS Select Treatment-Related AEs of Interest

How Do We Choose Between Agents?

Bone Health Preservation

New Imaging Modalities

Conclusion

Abbreviations

Abbreviations (cont)